Clinical Trials

Clinical trials are essential to the development of innovative therapies, and we are committed to sharing information about our trials with patients, healthcare professionals, and the medical and scientific communities.

Healthcare professionals interested in learning more about our trials can email ClinicalTrialInfo@connectpharm.com. Patients interested in learning more about our clinical trials can speak with their healthcare providers.

China Pivotal Trial in Atopic Dermatitis

A Study Evaluated the Efficacy and Safety of rademikibart (CBP-201) in Moderate to Severe Atopic Dermatitis in China (Completed)

Key Inclusion Criteria

  • Adults 12-75 years of age at the screening visit with AD according to American Academy of Dermatology Consensus Criteria.
  • AD for at least 1 year prior to the baseline visit with an inadequate response to AD treatment with a topical regimen of corticosteroids, phosphodiesterase inhibitors or calcineurin inhibitors, or for whom topical treatments are otherwise medically inadvisable.

Click here for topline results.

Type 2 Inflammatory Asthma

A phase 2 clinical trial to evaluate the safety and efficacy of CBP-201 in patients with Moderate to Severe persistent asthma with Type 2 inflammation. (Completed)

Key Inclusion Criteria

  • Adults 18-75 years of age with a diagnosis of asthma for a minimum of 12 months, based on the Global Initiative for Asthma (GINA) 2020 guidelines.
  • Asthma patients receiving treatment with medium to high dose inhaled corticosteroids (ICS) in combination with at least 1 additional reliever/controller for at least 90 days. Patients requiring maintenance oral corticosteroids (OCS) with a stable dose ≤ 10mg/day prednisone or equivalent OCS in addition to ICS are also eligible.

Click here for topline results.

Ulcerative Colitis

A Phase 2 clinical trial to evaluate the safety and efficacy of CBP-307 in patients with moderate-to-severe ulcerative colitis (UC). (Completed)

Key Inclusion Criteria

  • Adults 18-75 years of age with a diagnosis of UC at least three months prior to screening, which should include clinical and endoscopic evidence of UC.
  • Moderate-to-severe UC within 14 days prior to the first dose of study drug, based on a complete Mayo score of 6-12 and endoscopic score > 2.

Click here for topline results.

Global Phase 2b Trial in Atopic Dermatitis

A Phase 2b clinical trial evaluated the safety and efficacy of rademikibart (CBP-201) for the treatment of moderate-to-severe atopic dermatitis (AD) in adult subjects. (Completed)

Key Inclusion Criteria

  • Adults 18-75 years of age at the screening visit with AD according to American Academy of Dermatology Consensus Criteria.
  • AD for at least 1 year prior to the baseline visit with an inadequate response to AD treatment with a topical regimen of corticosteroids, phosphodiesterase inhibitors or calcineurin inhibitors, or for whom topical treatments are otherwise medically inadvisable.

Click here for topline results.

Pruritus Associated with Atopic Dermatitis

A Phase 1 clinical trial to assess safety, tolerability and Pharmacokinetics of CBP-174 in healthy adults. (Completed)

Click here for Phase 1 results.